Endophthalmitis prophylaxis has always been a concern around cataract surgery. Unfortunately, patient compliance with postoperative drops may be a contributor to this dreaded infection. This month, Cynthia Matossian, MD, FACS, and Audrey Talley Rostov,…
In our practice at Minnesota Eye Consultants, we are committed to what I call an “integrated eye care delivery model.” We have 13 ophthalmologists and 13 optometrists. To support these doctors and the six offices and four ASCs we staff, Minnesota Eye Consultants employs about 55 certified ophthalmic technologists/technicians/assistants and optometric assistants, 26 RNs/LPNs, seven certified operating room technicians, six opticians and, starting 5 years ago, a physician assistant, up to three PAs today.In our practice, the PAs practice independently within our state of Minnesota’s scope of practice laws, much (Read more...)
Among the various physician extenders for an ophthalmic practice, a physician assistant may very well be the most valuable for patient care, patient convenience and the practice’s financial well-being due to the wide scope of services that a physician assistant can perform. However, practices must be willing to commit the time and resources necessary to properly train such a medical professional.“Having a physician assistant (PA) is a critical part of the eye care team, but not necessarily more or less valuable than having an optometric provider,” Michael L. Gilbert, MD, (Read more...)
Recent FDA activity includes the addition of an ocular indication for AbbVie’s Humira and the issuance of two complete response letters, one to Ocular Therapeutix and one to Valeant, citing manufacturing concerns. Ocular Surgery News compiled these stories from Healio.com/OSN.The FDA has approved Humira for the treatment of noninfectious intermediate and posterior uveitis and panuveitis, according to a press release from AbbVie. Read more
Dynamic light scattering may be used to determine whether age-related nuclear cataracts are associated with loss of a critical protein in the crystalline lens.In one study, the authors set out to corroborate a previous cross-sectional study showing th…
REYKJAVIK, Islande–(BUSINESS WIRE)–Oculis a annoncé aujourd’hui avoir bouclé un tour de financement de série A mené par Brunnur Ventures et Silfurberg. Le capital nouvellement levé soutiendra le développement continu de la plateforme brevetée de libération de médicaments de la société pour les nanoparticules solubilisantes (SNP) et des candidats médicaments de la société, incluant les premières gouttes ophtalmiques topiques pour le traitement de l’œdème maculaire diabétique. Plateforme de lib